Step Pharma

Step Pharma is dedicated to developing a new class of oral nucleotide synthesis inhibitors targeting CTPS1, aimed at improving the treatment of a range of cancers and autoimmune diseases. The company has identified several CTPS1 inhibitors, with the most advanced being STP938, which is being prepared for clinical research in T-cell malignancies.